



CELEBRATING 50 YEARS

Bath Institute for Rheumatic Diseases
Arthritis | Research | Education

Annual Report and Accounts 2024-25



Trustees' Annual Report for the year ended 31 March 2025

Contents	Page
Charity information	1
Trustees' Annual Report	2
Statement of directors' responsibilities	12
Independent Examiner Report	14
Funds Statements:-	
Statement of Financial Activities	16
Prior Year statement	17
Statement of total recognised gains and losses	18
Income and Expenditure account	20
Balance sheet	21
Notes to the accounts	23

Trustees' Annual Report for the year ended 31 March 2025

Charity information

The Trustees present their Report and Accounts for the year ended 31 March 2025, which also comprises the Directors' Report required by the Companies Act 2006.

The charity name

The legal name of the charity is:-
Bath Institute for Rheumatic Diseases. The charity is also known by its operating name, BIRD.

The charity's areas of operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1040650. The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

Department D1
Wolfson Building, Royal United Hospital Bath,
BA1 3NG
Telephone 01225 336363

BIRD@birdbath.org.uk www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in office for the period covered by the report:

Chris Johns
Dr Amanda Mackenzie
Prof Neil McHugh
Prof Bernie Morley emeritus - **Chair**
Shane O'Reilly
Prof Raj Sengupta
Jim Sherwin
Linda Snelus
Dr William Tillet

Objects and activities of the charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

Strategy

We continue to follow our strategy with the central purpose of balancing reliance on investment performance over the long term with more grant and donor fundraising, which in turn requires a raised profile and clearer articulation of impact.

- *BIRD attended the British Society of Rheumatologists conference for the third time to highlight our work*
 - *Reaching record-breaking attendance of 730 healthcare professionals for educational events*
- *Launch of a newly redesigned website in November 2024*
- *BIRD co-hosted the fourth Skin@Bath Network Symposium with 198 participants from 12 countries*
- *BIRD celebrated significant milestones on its 50th anniversary in 2025*

We finish the financial year with **£1,548,091** in funds, down from **£1,791,638** at the same point last year, reflecting the need to draw down additional funds due to the instability in the world stock markets.

BIRD's income totalled **£104,455**, but expenditure was **£240,479**. In total, BIRD awarded almost **£60,000*** in **grants and bursaries** to clinician researchers and early career researchers and spent over **£50,000 on patient and public engagement**.

Grants awarded for research

BIRD funds research projects in rheumatic diseases which:

- *Help to promote and advance medical knowledge*
- *Improve treatments for patients*
- *Encourage collaboration between clinicians and research scientists*
- *Supports the next generation of researchers into bone and joint diseases*

The **focus** is on **pump prime funding** for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The **guideline for grant** amounts is up to **£20,000** (but greater amounts may be considered) that would be ideally suited to **pilot studies, preliminary research, tests of clinical effectiveness** or would enable other grants to be made for research.

It aims to **promote and advance medical science, pump-priming research**, help **researchers in the early stages of their careers**, help clinicians to be research active, **encourage collaborations** between clinicians and research scientists, and **ensure patients are involved in research**.

**£32,865 after write backs, due to project cancellations.*

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

Since 2016 BIRD has funded **over 30 projects**, with over **700 patients involved in a meaningful way**, helping to advance medical science, with **grants generating at least 30 academic publications so far**.

In total, £54,308 for research was awarded:

£16,376 to Dr Anita McGrogan, Dr Sarah Tansley & Christine MacFadyen for a project on Pregnancy outcomes in Systemic Lupus Erythematosus.

This project aims to better understand specific risks for patients with lupus who are pregnant, including the risk of miscarriage, stillbirth, and congenital malformations. They hope that this will provide valuable information for women in the UK with lupus who are considering pregnancy, allow improved planning for maternity care in lupus and that it will form a basis for future research.

£17,933 to Dr Jen Pearson & Dr Caroline Flurey for a project to understand the experience of men living with Fibromyalgia (FM).

This project aims to understand what it's like to be a man with fibromyalgia, how men manage their condition, and what support they would like from their clinical team. They will look into this by talking to 30-40 men with fibromyalgia either individually or in groups with other men (depending on their preference). Patients in this study will come from one NHS Trust in the UK and will be invited through national charities and social media. This will be the first study in the UK to talk specifically to men with fibromyalgia about their experiences and needs.

£19,999 to Dr Sarah Tansley for the project titled 'Does Immunoprecipitation coupled with high performance liquid chromatography mass spectrometry provide equivalent autoantibody diagnostic capabilities to conventional radio-immunoprecipitation?'

This project will ultimately help answer questions that matter to patients such as 'what does the future hold for me?' Autoantibodies (AAb) are a blood test used by doctors to help diagnose rheumatic diseases like myositis and scleroderma. Different AAb are linked to different diseases and to complications like lung disease and cancer. The AAb tests used by hospitals don't always work well and often give the wrong result. Missed AAb can delay diagnosis and prevent personalised care. The best AAb test is called radio-immunoprecipitation. This test is accurate but time- consuming, expensive, and not widely available. A new test called immunoprecipitation-mass spectrometry (IP-MS) could overcome these problems. So far IP-MS has only been used by one research team, and more information on its effectiveness is needed. In this study, they will look at the ability of IP-MS to detect key Aab in Bath. Dr Tansley will also use IP-MS to find new AAb. Going forwards, it is believed IP-MS could increase the availability of accurate AAb testing, help find new AAb and lead to new research opportunities.



Trustees' Annual Report for the year ended 31 March 2025

Bursaries

Building on the recent success of early career researchers **BIRD awarded £5,218.04 for bursaries to attend BSR and EULAR in 2024-2025.**

This is to **encourage health professionals** based in the Royal National Hospital for Rheumatic Diseases (RNHRD) **to attend these key national and international conferences** as part of **BIRD's mission to encourage clinical staff to be research-active** and to maintain the RNHRD's reputation for research excellence.

For the **third consecutive year**, BIRD took a stand at the annual **British Society for Rheumatology Conference in Liverpool** to **showcase its Patient Engagement programme**. This was to promote and network for further patient engagement opportunities.



Thank you so much to BIRD for enabling me to attend. It was an absolute joy to share in several days of learning, networking and personal growth with academic and clinical colleagues, and a definite highlight of my PhD thus far! Rosie Barnett

Many thanks to BIRD for facilitating my attendance at EULAR 2024 in Vienna. It was an enjoyable experience learning from top rheumatology experts and networking with colleagues. I plan to apply the key lessons in my daily practice to enhance patient care. Please keep up the good work. Akpabio Akpabio

Thanks so much for BIRD support to attend my first BSR meeting. It was great to hear from leading clinicians and researchers in the field of AxSpA and axial PsA, and also be able to attend other sessions covering a range of the rheumatology field. Ben Davies

So grateful for your support to be here - so many inspiring and interesting sessions attended, and many yet to come. Thank you. Jade Skeates

BIRD's education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the **Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education and Research Trust**. The programme was **attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals**.

BIRD provided the administration support including the accreditation and sponsorship where necessary, for educational events reaching **730 healthcare professionals**, a record breaking year.

Each of the **training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust** (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

The Education Programme was led by Dr Andrew Allard, Consultant Rheumatologist, and Fran Staples, Senior Administrator BIRD.

The programme for 2024/25 included the following events:

Two Bath & Bristol Bone Meetings were held in May and November 2024 for consultants and clinical staff.

The South West Axial Spondyloarthritis Group Regional Meeting was held in November 2024 for consultants and clinical staff. This meeting was an opportunity for all healthcare professionals working in the South West and South Coast areas, who have a strong interest in Axial Spondyloarthritis, to meet with their colleagues and discuss potential future collaborative research and quality improvement initiatives.

Two South West CTD & Vasculitis Regional Meetings were held in September 2024 and March 2025 for consultants and clinical staff.

The Primary Care Rheumatology Update Afternoon held in March 2025 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

The Axial Spondyloarthritis for Primary Care Webinar was held in May 2024 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

The Fibromyalgia Update for Primary Care Webinar was held in December 2024 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

Ratings as an average of all meetings
Excellent/good rating for relevance of this meeting to your educational needs **92%**

Excellent/good rating for overall quality of the education offered **100%**

Trustees' Annual Report for the year ended 31 March 2025

BIRD co-hosted the fourth **Skin@Bath Network Symposium** with **198 participants** from **12 countries**. **170** of whom attended in person. The Symposium featured **40 talks** over two days. Given by **prestigious national and international clinicians, healthcare professionals and scientists** as well as **early career researchers, medical trainees** and **postgraduate students**.



The **Nick Hall Memorial Bursary** continued for this conference, giving bursaries to honour his legacy by financially supporting the participation of three young researchers and medical trainees either at postgraduate or early career stages of their career to attend the Skin@Bath Network Symposium. **Applicants were restricted to PhD students, postdoctoral researchers, and medical trainees** and applications from less privileged countries are prioritised in the selection stage.

The Patient and Public Engagement Programme

The Programme vision is to help more patients to be involved in research and deepen their understanding of Rheumatic Diseases and the latest research and treatment.

With the twin aims of:

Patients having a deeper knowledge of Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals

Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Over the 2024-2025 period, the Patient Engagement and Involvement (PPIE) programme continued to evolve and develop around patient audience needs. It provides opportunities for patients to connect, learn and share through a flexible and innovative mix of media.



Trustees' Annual Report for the year ended 31 March 2025

Patient Engagement Activities

Webinars - Six patient information webinars were held covering **Axial Spondylarthritis**, **Psoriatic arthritis** and **Lupus** with a total attendance of **370 participants** across all webinars. **Feedback** was **overwhelmingly positive** with attendees expressing **appreciation for the sessions** and suggestions for future topics.



Patient Events - Three patient events were delivered during the year:

- **Professor Tim Spector event** sponsored through Bath Festivals **engaging 103 patients and attended by over 600 people**. This raised **awareness of the charity** with a **full page article** on page three about the charity in the **Bath Chronicle**
- **Seated movement and Dance workshop** with 12 patient attendees
- **Osteoporosis event** with 39 patient attendees

BIRD also hosted an exhibition in the Bath Central Library during the month of March. **Celebrating 50 years of working with the Royal National Hospital for Rheumatic Diseases** and local arthritis and rheumatology patients;



Trustees' Annual Report for the year ended 31 March 2025

Videos BIRD now has **24 videos available** on their **YouTube channel**. These continue to be a **valuable resource** with **significant growing viewership**, especially through the Inhealth App used by patients at the RNHRD.



Podcasts - The **podcast programme** remains successful, with **impressive listening figures** that **enable thousands of patients** and their families nationwide to **access information** about a **wide range of rheumatology conditions**.

Patient Research Involvement

The **Patient Research Panel**, consisting of **46 committed volunteers**, provided **feedback on survey design** and **research opportunities** to **academic and clinical researchers** during the year.

A variety of Patient and Public Involvement and Engagement (PPIE) activities were facilitated, including:

- **Virtual Reality motor impairment project**
- **Research Grant Bid (LEAP) for axSpA**
- **Virtual Reality Research in Flare Ups/ axSpA**
- **TULIPS (PsA) project**
- **Wearable technology research in axSpA**
- **Gemini Study (RMD+COPD)**
- **PsA X-Rays Workshop**
- **AxSpa/neurofeedback study**
- **PsA biologics Workshop**
- **Fibromyalgia cognitive issues research**

One researcher commented:

"The research engagement support BIRD provides through the PPE programme has been invaluable for furthering our research into how technology can support patients. Having worked with the team across several projects, they have been incredibly supportive at every stage of the process and helped to ensure the successful delivery through recruitment and engagement with patients which provides important feedback and actionable improvements to our research."

This comment **highlights the value of early-stage PPI support** and the **power of direct patient engagement** aimed at **improving the lives** of those living with **chronic conditions**.

Awareness raising


The reach of BIRD continued to expand through ongoing investment in social media platforms including Facebook, Instagram and LinkedIn.

Trustees' Annual Report for the year ended 31 March 2025

The charity achieved notable growth with:

- **Steady increase in Facebook followers with higher content interactions (2.7K in 2025 compared to 2.2K previously)**
- **Increased website visits from 4.7K to 7.1K**
- **Growth in Instagram followers from 112 to 179**
- **LinkedIn connections increasing from 109 to 161**

A significant milestone was the launch of a newly designed website in November 2024, updating and enhancing BIRD's digital presence.



The **BIRD newsletter programme** continued with **nine general public newsletters** and **stakeholder newsletters** sent throughout the year, reaching a **growing audience of 1,302 active contacts** (general public) and **159 stakeholders**.

The **following people and trusts** gave **significant donations and legacies** for which **BIRD is very grateful**, and their names were added to the Benefactors Board, recently moved to the entrance of the Royal National Hospital for Rheumatic Diseases

The Champniss Trust; Erika Wiesenmueller-Potter and Barry Potter; Derek Pitman; Don and Janet Templeton; Medlock Charitable Trust.

Some of the achievements and performance of the charity in terms of public benefit:

The total amount of grants and bursaries awarded for research into rheumatic diseases exceeded £60,000

730 professionals attended BIRD training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics, a record breaking year

85% of patients who attended the Lupus webinar **felt they understood their condition and would manage their condition better after the webinar.**

46 committed volunteers, provided feedback on survey design and research opportunities to academic and clinical researchers during the year.

Overall, the charity's beneficiaries: scientific academia and patients, carers and their families benefitted from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.

Trustees' Annual Report for the year ended 31 March 2025

Structure, governance and management of the charity

The governing body is the **Council of Management** made up of 9 trustees. The chair is now Professor Bernie Morley emeritus, Council of Management meets triannually

Three committees report to the Council of Management.

These are the **triannual Finance Committee**, chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns Linda Snelus and Bernard Fairhurst; **the biannual Research Committee**, chaired by Professor Bernie Morley emeritus, members are Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr Sarah Skeoch, Dr Paula Smith, Dr Theresa Smith, Frank Sweeting and Dr Sarah Tansley; and the **triannual Education & Engagement Committee**, chaired by Shane O'Reilly, members are Dr Andrew Allard, Patricia Mattinson and Jessie Naish. All committees are supported by relevant contract staff in attendance.

Bankers

Unity Trust Bank, 9 Brindley Place, Birmingham B1 2HB

CCLA Investment Management Ltd, COIF Charity Funds, 1 Angel Lane, London EC4R 3AB

Solicitors

Stone King, 13 Queen Square, Bath BA1 2HJ

Accountants

DR Hicks, Chartered Accountants, 107 Penn Hill Road, Bath BA1 3RU

Financial review

The financial position of the charity at 31 March 2025 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2025 £	2024 £
Net income	(242,427)	115,039
Unrestricted Revenue Funds available for the general purposes of the charity	1,517,547	1,754,967
Designated Revenue Funds	14,843	18,478
Total Unrestricted Funds	1,532,390	1,773,445
Restricted Revenue Funds	16,821	18,193
Total Funds	1,549,211	1,791,638

The Finance Committee, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.

BIRD's reserves policy is to

- hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
- retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a 'balanced' return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity's aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity's reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised. Dividends and interest are paid away on a quarterly basis.

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £90,000, depending on the quality of applications received and will encourage clinicians to undertake research and early stage career researchers. It will help thousands of patients to understand their disease and treatment better and, with renewed focus, hundreds to engage with research. It will also continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. BIRD will work on a strategy to achieve that during the year ahead.

Next year BIRD will undertake a recruitment exercise for new Trustees and committee members as part of good succession planning.

Details of The Independent Examiner

Tom Case

**Member of The Institute of Chartered
Accountants in England and Wales 20**

Goodwood Way

**Cepen Park South Chippenham Wiltshire
SN14 0SY**

Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008.

Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

Trustees' Annual Report for the year ended 31 March 2025

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that, on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.
Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 16 to 37.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the Board of Trustees on 4 July 2025.



Bernie Morley
Chair

I report to the Trustees on my examination of the financial statements of the charitable company on pages 16 to 37 for the year ended 31 March 2025 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 23.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider

in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide.

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

- The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;
- This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;
- and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-
- accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;
- the financial statements do not accord with those records; or

- the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;
- have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tom Case - Independent Examiner

The Institute of Chartered Accountants in
England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire SN14 0SY

This report was signed on 02 October 2025.

Statement of Financial Activities for the year ended 31 March 2025

	SORP Ref	Current Unrestricted Funds	Current Restricted Funds	Current Total Funds	Prior Total Funds
		2025 £	2025 £	2025 £	2024 £
Income & Endowments from:					
Donations & Legacies	A1	6,244	-	6,244	38,464
Charitable activities	A2	55,625	100	55,725	24,625
Investments	A4	42,485	-	42,485	43,797
Total income	A	104,354	100	104,454	106,886
Expenditure on:					
Charitable activities	B2	240,127	352	240,479	238,680
Total expenditure	B	240,127	352	240,479	238,680
Net gains/(losses) on investment	B4	(106,402)	-	(106,402)	246,833
Net income for the year		(242,175)	(252)	(242,427)	115,039
Transfers between funds	C	1120	(1,120)	-	-
Net income after transfers	A-B-C	(241,055)	(1,372)	(242,427)	115,039
Net movement in funds		(241,055)	(1,372)	(242,427)	115,039
Reconciliation of funds:-	E				
Total funds brought forward		1,773,445	18,193	1,791,638	1,676,599
Total funds carried forward		1,532,390	16,821	1,549,211	1,791,638

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.
All activities derive from continuing operations

The notes attached on pages 23 to 37 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2025

Analysis of prior year total funds as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Income & Endowments from:				
Donations & Legacies	A1	38,464	-	38,464
Charitable activities	A2	24,550	75	24,625
Investments	A4	43,797	-	43,797
Total income	A	106,811	75	106,886
Expenditure on:				
Charitable activities	B2	238,208	472	238,680
Total expenditure	B	238,208	472	238,680
Net gains/(losses) on investments	B4	246,833	-	246,833
Net income for the year		115,436	(397)	115,039
Transfers between funds	C	89	(89)	-
Net income after transfers		115,525	(486)	115,039
Net movement in funds		115,525	(486)	115,039
Reconciliation of funds:-				
	E			
Total funds brought forward		1,657,920	18,679	1,676,599
Total funds carried forward		1,773,445	18,193	1,791,638

All activities derive from continuing operations

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement

The notes attached on pages 23 to 47 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2025

Statement of Total Recognised Gains and Losses for the year ended 31 March 2025

	2025 £	2024 £
(Deficit)/Surplus for the year :-		
Net excess of income over expenditure from operations before tax	(136,025)	(131,794)
	-	-
<i>Income from operations before tax in the Statement of Financial Activities</i>	(136,025)	(131,794)
Unrealised (losses)/gains on investments	(106,402)	246,833
Net Movement in funds before taxation	(242,427)	115,039
Funds generated in the year as shown on Statement of Financial Activities	(242,427)	115,039

Resources applied in the year ended 31 March 2025 towards fixed assets for Charity use

	2025 £	2024 £
Funds generated in the year as detailed in the SOFA	(242,427)	115,039
Resources applied on functional fixed assets	(300)	(1,549)
Net resources available to fund charitable activities	(242,727)	113,490

Statement of Financial Activities for the year ended 31 March 2025

Movements in revenue and capital funds for the year ended 31 March 2025

Revenue accumulated funds

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last Year Funds 2024 £
Accumulated funds brought forward	1,773,445	18,193	1,791,638	1,676,599
Recognised gains and losses before transfers	(242,175)	(252)	(242,427)	115,039
	1,531,270	17,941	1,549,211	1,791,638
(From)/To unrestricted revenue funds	1,120	(1,120)	-	-
Closing revenue funds	1,532,390	16,821	1,549,211	1,791,638

Designated revenue funds included within the unrestricted funds above

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last Year Funds 2024 £
At 1 April			18,478	26,886
Transfer (to)/from revenue accumulated funds			(3,635)	(8,408)
At 31 March			14,843	18,478

The purposes for which these funds have been designated are described in Note 20 to the accounts.

Revenue accumulated funds	1,517,547	16,821	1,534,368	1,773,160
Revenue designated funds	14,843	-	14,843	18,478
Total funds	1,532,390	16,821	1,549,211	1,791,638

Statement of Financial Activities for the year ended 31 March 2025

Income and Expenditure Account for the year ended 31 March 2025 as required by the Companies Act 2006

	2025 £	2024 £
Income		
Income from operations	61,969	63,089
Investment income		
Income from investments, other than interest receivable	42,485	43,797
Gross income in the year before exceptional items	104,454	106,886
Gross income in the year including exceptional items	104,454	106,886
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	239,370	237,788
Depreciation and amortisation	635	430
Governance costs	474	462
Total expenditure in the year	240,479	238,680
Net income before tax in the financial year	(136,025)	(131,794)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(136,025)	(131,794)
Retained surplus for the financial year	(136,025)	(131,794)

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 23 to 37 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2025

Balance Sheet as at 31 March 2025

	SORP Note Ref	2025 £	2024 £
Fixed assets A			
Tangible assets	9 A2	1,451	1,786
Investments held as fixed assets	10 A4	1,615,394	1,871,796
Total fixed assets		1,616,845	1,873,582
Current assets	B		
Debtors	12 B2	6,207	5,774
Cash at bank and in hand	B4	55,499	44,602
Total current assets		61,706	50,376
Creditors: amounts falling due within one year	13 C1	(129,340)	(132,320)
Net current assets		(67,634)	(81,944)
The total net assets of the charity		1,549,211	1,791,638

The total net assets of the charity are funded by the funds of the charity, as follows:-

Restricted funds			
Restricted Revenue Funds	17 D2	16,821	18,193
Unrestricted Funds			
Unrestricted Revenue Funds	17 D3	1,517,547	1,754,967
Designated Funds			
Designated Revenue Funds	17 D3	14,843	18,478
Total charity funds		1,549,211	1,791,638

Statement of Financial Activities for the year ended 31 March 2025

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



James Sherwin

Trustee and Chair of the Finance Committee

Approved by the Board of Trustees on
4 July 2025

The notes attached on pages 23 to 37 form an integral part of these accounts.

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material

uncertainties about the charity's ability to continue as a going concern.

Risks and future assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Notes to the Accounts for the year ended 31 March 2025

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition. Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery 20 % reducing balance

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Financial instruments including cash and bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes.

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law.

There are no endowment funds.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Significance of financial instruments to the charity's position

There are no significant implications of financial instruments to the charity's financial position or performance.

5 Net surplus before tax in the financial year

	2025 £	2024 £
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	635	430

Notes to the Accounts for the year ended 31 March 2025

6 Investment gains

Unrealised gains /(losses) and writing down of carrying values

	Current year Unrestricted Funds 2025	Current year Restricted Funds 2025	Current year Total Funds 2025	Prior Year Total Funds 2024
Listed investments - Unrealised	(106,402)	-	(106,402)	246,833
Total unrealised gains/(losses) etc	(106,402)	-	(106,402)	246,833
Total realised and unrealised gains	106,402)	-	(106,402)	246,833

All the gains and losses in the prior year was unrestricted.

Unrealised gains /(losses) and writing down of carrying values

Listed investments - Unrealised	246,833	-	246,833
Total unrealised gains/(losses) etc	246,833	-	246,833
Total realised and unrealised gains	246,833	-	246,833

7 Staff costs and emoluments

<i>Labour costs</i>	2025 £	2024 £
Gross salaries, labour and related costs	126,781	133,060
	126,781	133,060

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

8 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

Notes to the Accounts for the year ended 31 March 2025

9 Tangible fixed assets

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
Cost				
At 1 April 2024	-	13,489	-	13,489
Additions	-	300	-	300
At 31 March 2025	-	13,789	-	13,789
Depreciation				
At 1 April 2024	-	11,703	-	11,703
Charge for the year	-	635	-	635
At 31 March 2025	-	12,338	-	12,338
Net book value				
At 31 March 2025	-	1,451	-	1,451
At 31 March 2024	-	1,786	-	1,786

10 Investments held as fixed assets

	Investments in subsidiaries	Listed investments	Other Classes of Investment	Total
	£	£	£	£
Carrying values of investments				
At 1 April 2024	2	1,871,794	-	1,871,796
Revaluation at 31 March 2025	-	(106,402)	-	(106,402)
Disposals	-	(150,000)	-	(150,000)
At 31 March 2025	2	1,615,392	-	1,615,394
Analysis between fair value and historical cost				
Investments as above held at fair value	2	1,615,392	-	1,615,394

Notes to the Accounts for the year ended 31 March 2025

11 Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the ten years ending 31st March 2025.

A summary of the unaudited financial statements of the subsidiary is :-

	2025 £	2024 £
Assets and Funds		
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
Aggregate amount of funds	(547)	(547)

Profit and Loss

<i>Net profit for the year before tax</i>	-	-
<i>Net profit for the year after tax and Gift Aid</i>	-	-

Funds retained within charitable subsidiaries

	2025 £	2024 £
The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are	-	-
	-	-

12 Debtors

	2025 £	2024 £
Trade debtors	5,946	5,513
Prepayments and accrued income	261	261
	6,207	5,774

Notes to the Accounts for the year ended 31 March 2025

13 Creditors: amounts falling due within one year

	2025 £	2024 £
Trade creditors	19,874	42,542
Accruals	13,200	9,900
Other creditors	96,266	79,878
	129,340	132,320

14 Income and Expenditure account summary

	2025 £	2024 £
At 1 April 2024	1,544,805	1,676,599
Transfers in for the year	-	-
At 1 April 2024	1,544,805	1,676,599
Surplus after tax for the year	(136,025)	(131,794)
At 31 March 2025	1,408,780	1,544,805

15 No related party transactions

There were no transactions with related parties in the year.

16 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2025	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £
Tangible Fixed Assets	1,451	-	-	1,451
Investments at valuation:-				
Fixed asset investments	1,615,394	-	-	1,615,394
Current Assets	26,407	18,478	16,821	61,706
Current Liabilities	(130,460)	-	-	(130,460)
	1,512,792	18,478	16,821	1,548,091
At 1 April 2024	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £
Tangible Fixed Assets	1,786	-	-	£1,786
Investments at valuation:-				
Fixed asset investments	1,871,796	-	-	1,871,796
Current Assets	13,705	18,478	18,193	50,376
Current Liabilities	(132,320)	-	-	(132,320)
	1,754,967	18,478	18,193	1,791,638

Notes to the Accounts for the year ended 31 March 2025

17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2024	Movement in funds in 2025 see note 18	Transfers between funds in 2025 see note 19	Funds carried forward to 2026
	£	£	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	1,754,967	(242,175)	4,755	1,517,547
Designated Revenue Funds	18,478	-	(3,635)	14,843
Total unrestricted and designated funds	1,773,445	(242,175)	1,120	1,532,390
<i>Restricted funds:-</i>				
Restricted - CRPS Conference	1,120	-	(1,120)	-
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Metabolic Bone Disease	2,928	(252)	-	2,676
Total restricted funds	18,193	(252)	(1,120)	16,821
Total charity funds	1,791,638	(242,427)	-	1,549,211

18 Analysis of movements in funds over the year as shown in Note 17

	Income 2025 £	Expenditure 2025 £	Other Gains & Losses 2025 £	Movement in funds 2025 £
<i>Unrestricted and designated funds:-</i>				
Unrestricted Revenue Funds	104,354	(240,127)	(106,402)	(242,175)
<i>Restricted funds:-</i>				
Restricted - Metabolic Bone Disease	100	(352)	-	(252)
	104,454	(240,479)	(106,402)	(242,427)

19 Details of transfers between

The transfers shown in note 17 above are:-

	2025 £
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'.	4,755
To/(from) Designated Revenue Funds	(3,635)
To/(from) Restricted Revenue Funds	(1,120)
Net transfers	-

Notes to the Accounts for the year ended 31 March 2025

20 The purposes for which the funds

Unrestricted and designated funds:-

Unrestricted Revenue Funds These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

Designated Revenue Funds Funds specific for this purpose.

Restricted funds:-

Restricted Revenue Funds Funds specific for this purpose.

21 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

22 Donations, Grants and Legacies

	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Donations and gifts from individuals				
Donations	6,244	-	6,244	38,462
Total donations and gifts from individuals	6,244	-	6,244	38,462

	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Legacies receivable				
Legacies receivable	-	-	-	2
Total legacies receivable	-	-	-	2

Total Donations, Grants and Legacies

Total Donations, Grants and Legacies	A1	6,244	-	6,244	38,464
---	-----------	--------------	----------	--------------	---------------

Notes to the Accounts for the year ended 31 March 2025

23 Income from charitable activities - Trading Activities

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Primary purpose and ancillary trading				
Education income	34,358	100	34,458	1,998
Other and recharged income	-	-	-	105
Service charges - BGPRT	16,685	-	16,685	17,558
Service charges - BRIT PACT	4,582	-	4,582	4,964
Total Primary purpose and ancillary trading	55,625	100	55,725	24,625

Not all the trading activities in the prior year were unrestricted

<i>Prior year</i>	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Primary purpose and ancillary trading			
Other and recharged income	30	75	105
Total Primary purpose and ancillary trading	24,550	75	24,625

Notes to the Accounts for the year ended 31 March 2025

24 Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Total income from charitable trading	55,625	100	55,725	24,625
Total from charitable activities A2	55,625	100	55,725	24,625

Not all the income in the prior year was unrestricted.

Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Total income from charitable trading	24,550	75	24,625
Income from funders	-	-	-
	24,550	75	24,625

25 Investment income

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Dividend Income	42,485	-	42,485	43,797
Total investment income A4	42,485	-	42,485	43,797

Notes to the Accounts for the year ended 31 March 2025

26 Expenditure on charitable activities - Direct spending

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Labour costs - charitable activities	126,781	-	126,781	133,060
Education costs	39,569	352	39,921	7,741
PPE Project costs	-	-	-	2,344
Total direct spending B2a	166,350	352	66,702	143,145

Not all the expenditure in the prior year was unrestricted.

27 Expenditure on charitable activities- Grant funding of activities

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Grants made to individuals	32,865	-	32,865	63,776
Total grantmaking costs B2c	32,865	-	32,865	63,776

Notes to the Accounts for the year ended 31 March 2025

28 Support costs for charitable activities

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Premises Expenses				
Rent	3,300	-	3,300	3,300
Administrative overheads				
Telephone, fax and internet	1,056	-	1,056	1,034
Stationery and printing	645	-	645	1,151
Marketing and promotion	22,427	-	22,427	14,926
Registration and licensing	3,025	-	3,025	1,622
IT support costs	1,630	-	1,630	2,380
Recharged expenses	-	-	-	72
Insurance	617	-	617	547
Trustees costs	296	-	296	177
Hospitality	268	-	268	472
Travel	1,007	-	1,007	20
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	3,612	-	3,612	4,033
Other legal and professional	1,774	-	1,774	1,017
Financial costs				
Bank charges	146	-	146	116
Depreciation	635	-	635	430
Total support costs	40,438	-	40,438	31,297

<i>Prior year</i>	Current Year Unrestricted Funds 2024 £	Current Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Recharged expenses	(400)	472	72
Total support costs - Prior Year	30,825	472	31,297

Notes to the Accounts for the year ended 31 March 2025

29 Other Expenditure - Governance costs

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Prior Year Total Funds 2025 £	Total Funds 2024 £
Independent Examiner's fees	474	-	474	462
Total Governance costs	474	-	474	462

All the expenditure in the prior year was unrestricted.

30 Total Charitable expenditure

<i>Current year</i>		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Total direct spending	B2a	166,350	352	166,702	143,145
Total grantmaking costs	B2c	32,865	-	32,865	63,776
Total support costs	B2d	40,438	-	40,438	31,297
Total Governance costs	B2e	474	-	474	462
Total charitable expenditure B2		240,127	352	240,479	238,680

<i>Prior year</i>		Current Year Unrestricted Funds 2024 £	Current Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Total direct spending	B2a	143,145	-	143,145
Total grantmaking costs	B2c	63,776	-	63,776
Total support costs	B2d	30,825	472	31,297
Total Governance costs	B2e	462	-	462
Total charitable expenditure B2		238,208	472	238,680



CELEBRATING 50 YEARS

Bath Institute for Rheumatic Diseases
Arthritis | Research | Education

Company Registration
Number 02908933
Charity Registration
Number 1040650